NEW YORK (GenomeWeb News) – Quest Diagnostics has received clinical laboratory approval from New York State for its ClariSure microarray-based comparative genomic hybridization post-natal test.

The ClariSure aCGH test was approved as an aid in detecting copy-number chromosomal abnormalities implicated in dozens of medical conditions including mental retardation, birth defects, and autism spectrum and developmental disorders, the Madison, NJ-based clinical lab firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.